Tumor cells and tumor vasculature

Tumor cells and tumor vasculature refers to a therapeutic strategy that targets both the malignant cell population and the supporting blood vessel network within the tumor microenvironment (Folkman, J., NEJM, 1971). This dual approach aims to directly kill cancer cells while simultaneously depriving them of oxygen and nutrients by disrupting the tumor's blood supply (Kerbel, R. S., NEJM, 2008). While tumor cells are characterized by genetic instability and rapid proliferation, the tumor vasculature is often composed of immature, leaky, and disorganized endothelial cells that express specific markers like VEGFR or integrins (Thorpe, P. E., Clin Cancer Res, 2004). Drugs interacting with this "target" include anti-angiogenic agents like bevacizumab and vascular disrupting agents like combretastatin A-4. However, because this term encompasses multiple cell types and diverse molecular pathways, it is classified as a physiological compartment rather than a single molecular target. This lack of molecular specificity makes it an "incorrect" target entry for databases focused on specific proteins or receptors.

Other names

Tumor microenvironmentTumor-associated vasculatureNeoplastic cells and tumor endotheliumTumor stroma and parenchyma

Dual-action targeting involving the inhibition of pro-angiogenic signaling (e.g., VEGF/VEGFR) to starve the tumor and direct cytotoxic action against malignant cells to induce apoptosis (Folkman, J., NEJM, 1971; Kerbel, R. S., NEJM, 2008).